Patents by Inventor Jhong-Jhe You

Jhong-Jhe You has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR T-CELL ACTIVATION
    Publication number: 20240026018
    Abstract: Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 25, 2024
    Inventors: Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Jeng-Horng Her
  • PD-L1 AND OX40 BINDING PROTEINS FOR CANCER REGULATION
    Publication number: 20230322939
    Abstract: Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 12, 2023
    Inventors: Jhong-Jhe YOU, Ching-Hsuan HSU, Po-Lin HUANG, Hung-Tsai KAN, Ting-Yi CHANG, Hsin-Ta HSIEH, Jeng-Horng HER
  • Bifunctional Proteins Combining Checkpoint Blockade for Targeted Therapy
    Publication number: 20230322931
    Abstract: Provided are bispecific proteins that comprise a binding domain binding cell surface protein and a vascular endothelial growth factor (VEGF) inhibiting domain. Provided also is an antibody-drug conjugate that comprises a therapeutic agent and an antibody or an antigen-binding fragment binding PD-L1 and/or a VEGF inhibiting domain, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding fragment by a linker.
    Type: Application
    Filed: June 26, 2023
    Publication date: October 12, 2023
    Inventors: Jeng-Horng Her, Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang
  • Bifunctional proteins combining checkpoint blockade for targeted therapy
    Patent number: 11780922
    Abstract: Provided are bispecific proteins that comprise a binding domain binding cell surface protein and a vascular endothelial growth factor (VEGF) inhibiting domain. Provided also is an antibody-drug conjugate that comprises a therapeutic agent and an antibody or an antigen-binding fragment binding PD-L1 and/or a VEGF inhibiting domain, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding fragment by a linker.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: October 10, 2023
    Assignee: AP Biosciences, Inc.
    Inventors: Jeng-Horng Her, Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang
  • CD137 antibodies for T-cell activation
    Patent number: 11725058
    Abstract: Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 15, 2023
    Assignee: AP Biosciences, Inc.
    Inventors: Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Jeng-Horng Her
  • PD-L1 and OX40 binding proteins for cancer Regulation
    Patent number: 11643470
    Abstract: Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: May 9, 2023
    Assignee: AP Biosciences, Inc.
    Inventors: Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Hung-Tsai Kan, Ting-Yi Chang, Hsin-Ta Hsieh, Jeng-Horng Her
  • ANTIBODIES FOR T-CELL ACTIVATION
    Publication number: 20200407456
    Abstract: Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 31, 2020
    Applicant: AP Biosciences, Inc.
    Inventors: Jhong-Jhe YOU, Ching-Hsuan HSU, Po-Lin HUANG, Jeng-Horng HER
  • Bifunctional Proteins Combining Checkpoint Blockade for Targeted Therapy
    Publication number: 20200299389
    Abstract: Provided are bispecific proteins that comprise a binding domain binding cell surface protein and a vascular endothelial growth factor (VEGF) inhibiting domain. Provided also is an antibody-drug conjugate that comprises a therapeutic agent and an antibody or an antigen-binding fragment binding PD-L1 and/or a VEGF inhibiting domain, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding fragment by a linker.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Inventors: Jeng-Horng Her, Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang
  • Monospecific and Bispecific Proteins with Immune Checkpoint Regulation for Cancer Therapy
    Publication number: 20200270357
    Abstract: Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.
    Type: Application
    Filed: May 11, 2020
    Publication date: August 27, 2020
    Inventors: Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Hung-Tsai Kan, Ting-Yi Chang, Hsin-Ta Hsieh, Jeng-Horng Her